Nasdaq · CIK 0001867096
XERS Xeris Biopharma Holdings, Inc.
Insider trading from SEC Form 4. Last filing 12 d ago. Close $10.48 on Oct 9, 2026, +98% from the 52-week low and 0% from the high.
In brief
Xeris Biopharma Holdings, Inc. (XERS) has 74 SEC Form 4 filings on file from 14 insiders, the latest filed on Oct 2, 2026. In the last 90 days insiders made 0 open-market buys worth $0 and 10 open-market sells worth $1.2M, net -$1.2M.
43 open-market trades have been scored at XERS. The newest: Beth Hecht (See Remarks) sold $157k of stock on Oct 1, 2026, filed Oct 2, 2026, scored 21 (weak), under a 10b5-1 plan. The largest of the 43 shown: John Johnson (director) sold $977k on Dec 19, 2025, scored 60 (notable). 3 insiders sold within 14 days of each other around Oct 1, 2026.
24 Form 144 notices of planned sales are on file, the latest filed Oct 1, 2026.
Last 90 days
Net insider value
-$1.2M
more sold than bought
Buys
0
$0 by 0 insiders
Sells
10
$1.2M by 3 insiders
Insiders on file
14
with a Form 4 at this company
Price and insider trades, last year
XERSOct 9, 2026 · close 10.48
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Xeris Biopharma Holdings, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 21Weak | Beth Hecht See Remarks sell | $157k 16,666 shares | -1% | +75% from low-7% from high | |
| 21Weak | Kevin McCulloch See Remarks sell | $141k 15,000 shares | -1% | +75% from low-7% from high | |
| 16Weak | Steven Pieper See Remarks sell | $47k 5,000 shares | -0% | +75% from low-7% from high | |
| 23Weak | Kevin McCulloch See Remarks sell | $250k 25,000 shares | -2% | +86% from low-1% from high | |
| 21Weak | Beth Hecht See Remarks sell | $141k 16,666 shares | -1% | - | |
| 21Weak | Kevin McCulloch See Remarks sell | $127k 15,000 shares | -1% | - | |
| 16Weak | Steven Pieper See Remarks sell | $43k 5,000 shares | -0% | - | |
| 16Weak | Steven Pieper See Remarks sell | $43k 5,000 shares | -0% | +60% from low-14% from high | |
| 21Weak | Beth Hecht See Remarks sell | $134k 16,666 shares | -1% | +54% from low-18% from high | |
| 20Weak | Kevin McCulloch See Remarks sell | $120k 15,000 shares | -1% | +54% from low-18% from high | |
| 26Weak | Steven Pieper See Remarks sell | $383k 45,000 shares | -3% | +78% from low-15% from high | |
| 21Weak | Beth Hecht See Remarks sell | $134k 16,666 shares | -1% | +72% from low-19% from high | |
| 31Weak | Kevin McCulloch See Remarks sell | $723k 90,000 shares | -5% | +72% from low-19% from high | |
| 25Weak | Barbara-Jean Anne Bormann-Kennedy director sell | $98k 16,000 shares | -11% | +41% from low-38% from high | |
| 25Weak | Dawn Halkuff director sell | $122k 20,000 shares | -17% | +41% from low-38% from high | |
| 19Weak | John Johnson director sell | $91k 15,000 shares | -2% | +41% from low-38% from high | |
| 24Weak | Marla Persky director sell | $91k 15,500 shares | -11% | +35% from low-41% from high | |
| 20Weak | Beth Hecht See Remarks sell | $101k 16,667 shares | -1% | +40% from low-39% from high | |
| 5Weak | Beth Hecht See Remarks sell | $104k 16,667 shares | -1% | +46% from low-37% from high | |
| 13Weak | Beth Hecht See Remarks sell | $100k 16,667 shares | -1% | +53% from low-39% from high | |
| 15Weak | James Aloysius Brady director sell | $60k 10,834 shares | -11% | +42% from low-43% from high | |
| 5Weak | Beth Hecht See Remarks sell | $104k 16,667 shares | -1% | +63% from low-39% from high | |
| 5Weak | Beth Hecht See Remarks sell | $124k 16,667 shares | -1% | +107% from low-26% from high | |
| 20Weak | Kevin McCulloch See Remarks sell | $120k 15,000 shares | -1% | +154% from low-18% from high | |
| 7Weak | John Patrick Shannon Jr See Remarks sell | $176k 24,907 shares | -1% | +122% from low-28% from high | |
| 20Weak | Beth Hecht See Remarks sell | $124k 16,667 shares | -1% | +130% from low-26% from high | |
| 60Notable | John Johnson director sell | $977k 135,400 shares | -16% | +129% from low-26% from high | |
| 20Weak | Barbara-Jean Anne Bormann-Kennedy director sell | $106k 15,000 shares | -10% | +124% from low-28% from high | |
| 13Weak | Beth Hecht See Remarks sell | $117k 16,667 shares | -1% | +118% from low-30% from high | |
| 0Weak | John Patrick Shannon Jr See Remarks sell | $173k 23,242 shares | -1% | +150% from low-27% from high | |
| 13Weak | Beth Hecht See Remarks sell | $123k 16,667 shares | -1% | +157% from low-25% from high | |
| 13Weak | Marla Persky director sell | $120k 15,500 shares | -10% | +178% from low-4% from high | |
| 28Weak | Jeffrey W Sherman director sell | $335k 42,232 shares | -16% | +186% from low-1% from high | |
| 50Moderate | John Johnson director sell | $786k 107,500 shares | -11% | +164% from low-0% from high | |
| 47Moderate | Dawn Halkuff director sell | $309k 42,500 shares | -27% | +164% from low0% from high | |
| 29Weak | Kevin McCulloch See Remarks buy | $109k 25,000 shares | +1% | +58% from low-26% from high | |
| 27Weak | Beth Hecht See Remarks sell | $217k 40,000 shares | -3% | - | |
| 46Moderate | Jeffrey W Sherman director buy | $10k 5,400 shares | - | +79% from low-38% from high | |
| 46Moderate | Dawn Halkuff director buy | $9,954 5,410 shares | - | +77% from low-39% from high | |
| 45Moderate | Steven Pieper See Remarks buy | $55k 28,000 shares | +2% | +77% from low-39% from high | |
| 46Moderate | John P. Schmid director buy | $9,815 6,500 shares | - | +52% from low-47% from high | |
| 45Moderate | John Patrick Shannon Jr See Remarks buy | $50k 30,769 shares | +2% | +72% from low-41% from high | |
| 46Moderate | Marla Persky director buy | $10k 6,370 shares | - | +51% from low-48% from high |
Planned sales
Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales
| Filed | Seller | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Oct 1, 2026 | BETH HECHT Officer | 16,666 0.01% of outstanding | $159k | Oct 1, 2026 | $275k |
| Sep 28, 2026 | KEVIN MCCULLOCH Officer | 70,000 0.04% of outstanding | $637k | Sep 28, 2026 | $970k |
| Aug 12, 2026 | STEVEN PIEPER Officer | 20,000 0.01% of outstanding | $168k | Aug 12, 2026 | $383k |
| Jul 7, 2026 | STEVEN PIEPER Officer | 27,600 0.02% of outstanding | $231k | Jul 7, 2026 | $148k |
| Jul 6, 2026 | STEVEN PIEPER Officer | 17,400 0.01% of outstanding | $144k | Jul 6, 2026 | none |
| Jul 1, 2026 | BETH HECHT Officer | 49,998 0.03% of outstanding | $396k | Jul 1, 2026 | $205k |
| Jul 1, 2026 | KEVIN MCCULLOCH Officer | 120,000 0.07% of outstanding | $950k | Jul 1, 2026 | none |
| Jun 4, 2026 | Barbara-Jean Bormann-Kennedy Director | 16,000 0.01% of outstanding | $94k | Jun 4, 2026 | none |
| Jun 4, 2026 | DAWN HALKUFF Director | 20,000 0.01% of outstanding | $118k | Jun 4, 2026 | none |
| Jun 4, 2026 | JOHN H JOHNSON Director | 15,000 0.01% of outstanding | $88k | Jun 4, 2026 | none |
| Jun 3, 2026 | MARLA PERSKY Director | 15,500 0.01% of outstanding | $93k | Jun 3, 2026 | none |
| Mar 30, 2026 | JAMES BRADY Director | 10,834 0.01% of outstanding | $59k | Mar 30, 2026 | none |
| Mar 2, 2026 | BETH HECHT Officer | 66,668 0.04% of outstanding | $408k | Mar 2, 2026 | $248k |
| Jan 8, 2026 | KEVIN MCCULLOCH Officer | 60,000 0.04% of outstanding | $433k | Jan 8, 2026 | none |
| Dec 19, 2025 | JOHN H JOHNSON Director | 135,402 0.08% of outstanding | $977k | Dec 19, 2025 | none |
| Dec 12, 2025 | BARBARA-JEAN A BORMANN-KENNEDY Director | 15,000 0.01% of outstanding | $105k | Dec 12, 2025 | none |
| Nov 13, 2025 | JOHN SHANNON Director, Officer | 48,149 0.03% of outstanding | $365k | Nov 13, 2025 | none |
| Nov 12, 2025 | BETH HECHT Officer | 66,668 0.04% of outstanding | $515k | Nov 11, 2025 | none |
| Sep 11, 2025 | MARLA PERSKY Director | 15,500 0.01% of outstanding | $121k | Sep 11, 2025 | none |
| Aug 28, 2025 | JEFFREY SHERMAN Director | 42,232 0.03% of outstanding | $335k | Aug 28, 2025 | none |
| Aug 13, 2025 | JOHN H JOHNSON Director | 107,500 0.07% of outstanding | $786k | Aug 13, 2025 | none |
| Aug 12, 2025 | DAWN HALKUFF Director | 42,500 0.03% of outstanding | $309k | Aug 12, 2025 | none |
| May 9, 2025 | Fairley Ricki Louise Director | 56,667 0.04% of outstanding | $278k | May 9, 2025 | none |
| Mar 20, 2025 | Hecht Beth Officer | 40,000 0.03% of outstanding | $206k | Mar 20, 2025 | none |
Transactions
The newest 50 of 130 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 1, 2026 | Beth Hecht See Remarks | SOpen-market sale Common Stock10b5-1 | -16,666 | $9.41 | $157k | 1,111,130 | 12 d ago |
| Oct 1, 2026 | Kevin McCulloch See Remarks | SOpen-market sale Common Stock10b5-1 | -15,000 | $9.41 | $141k | 1,599,208 | 12 d ago |
| Oct 1, 2026 | Steven Pieper See Remarks | SOpen-market sale Common Stock10b5-1 | -5,000 | $9.41 | $47k | 1,351,053 | 12 d ago |
| Sep 28, 2026 | Kevin McCulloch See Remarks | SOpen-market sale Common Stock10b5-1 | -25,000 | $10.00 | $250k | 1,614,208 | 15 d ago |
| Sep 1, 2026 | Kevin McCulloch See Remarks | SOpen-market sale Common Stock10b5-1 | -15,000 | $8.49 | $127k | 1,639,208 | 43 d ago |
| Sep 1, 2026 | Steven Pieper See Remarks | SOpen-market sale Common Stock10b5-1 | -5,000 | $8.50 | $43k | 1,356,053 | 43 d ago |
| Sep 1, 2026 | Beth Hecht See Remarks | SOpen-market sale Common Stock10b5-1 | -16,666 | $8.49 | $141k | 1,127,796 | 43 d ago |
| Aug 1, 2026 | John Patrick Shannon Jr See Remarks | FTax withholding Common Stock | -36,645 | $8.08 | $296k | 2,898,933 | Aug 21, 2026 |
| Aug 1, 2026 | Kevin McCulloch See Remarks | FTax withholding Common Stock | -21,918 | $8.08 | $177k | 1,654,208 | Aug 21, 2026 |
| Aug 12, 2026 | Steven Pieper See Remarks | SOpen-market sale Common Stock10b5-1 | -5,000 | $8.50 | $43k | 1,361,053 | Aug 12, 2026 |
| Aug 3, 2026 | Beth Hecht See Remarks | SOpen-market sale Common Stock10b5-1 | -16,666 | $8.01 | $134k | 1,144,462 | Aug 4, 2026 |
| Aug 3, 2026 | Kevin McCulloch See Remarks | SOpen-market sale Common Stock10b5-1 | -15,000 | $8.02 | $120k | 1,676,126 | Aug 4, 2026 |
| Jul 6, 2026 | Steven Pieper See Remarks | SOpen-market sale Common Stock10b5-1 | -17,400 | $8.50 | $148k | 1,393,653 | Jul 7, 2026 |
| Jul 7, 2026 | Steven Pieper See Remarks | SOpen-market sale Common Stock10b5-1 | -27,600 | $8.52 | $235k | 1,366,053 | Jul 7, 2026 |
| Jul 1, 2026 | Nerissa Kreher director | AGrant or award Common Stock | +33,582 | $0.00 | $0 | 33,582 | Jul 2, 2026 |
| Jul 1, 2026 | Kevin McCulloch See Remarks | SOpen-market sale Common Stock10b5-1 | -90,000 | $8.03 | $723k | 1,691,126 | Jul 2, 2026 |
| Jul 1, 2026 | Beth Hecht See Remarks | SOpen-market sale Common Stock10b5-1 | -16,666 | $8.03 | $134k | 1,161,128 | Jul 2, 2026 |
| Jul 1, 2026 | Nerissa Kreher director | AGrant or award Stock Option (Right to Buy)derivative | +37,910 | $8.00 | $303k | 37,910 | Jul 2, 2026 |
| Jun 3, 2026 | Marla Persky director | SOpen-market sale Common Stock10b5-1 | -15,500 | $5.90 | $91k | 126,500 | Jun 5, 2026 |
| Jun 4, 2026 | Barbara-Jean Anne Bormann-Kennedy director | SOpen-market sale Common Stock10b5-1 | -16,000 | $6.09 | $98k | 126,500 | Jun 5, 2026 |
| Jun 4, 2026 | James Aloysius Brady director | AGrant or award Common Stock | +24,193 | $0.00 | $0 | 113,359 | Jun 5, 2026 |
| Jun 4, 2026 | Dawn Halkuff director | SOpen-market sale Common Stock10b5-1 | -20,000 | $6.09 | $122k | 95,000 | Jun 5, 2026 |
| Jun 4, 2026 | John Johnson director | SOpen-market sale Common Stock10b5-1 | -15,000 | $6.09 | $91k | 683,083 | Jun 5, 2026 |
| Jun 4, 2026 | Garheng Kong director | AGrant or award Common Stock | +24,193 | $0.00 | $0 | 238,337 | Jun 5, 2026 |
| Jun 4, 2026 | Marla Persky director | AGrant or award Common Stock10b5-1 | +24,193 | $0.00 | $0 | 150,693 | Jun 5, 2026 |
| Jun 4, 2026 | Barbara-Jean Anne Bormann-Kennedy director | AGrant or award Common Stock10b5-1 | +24,193 | $0.00 | $0 | 150,693 | Jun 5, 2026 |
| Jun 4, 2026 | James Aloysius Brady director | AGrant or award Stock Option (Right to Buy)derivative | +32,996 | $6.15 | $203k | 32,996 | Jun 5, 2026 |
| Jun 4, 2026 | Dawn Halkuff director | AGrant or award Common Stock10b5-1 | +24,193 | $0.00 | $0 | 119,193 | Jun 5, 2026 |
| Jun 4, 2026 | John Johnson director | AGrant or award Common Stock10b5-1 | +24,193 | $0.00 | $0 | 707,276 | Jun 5, 2026 |
| Jun 4, 2026 | Garheng Kong director | AGrant or award Stock Option (Right to Buy)derivative | +32,996 | $6.15 | $203k | 32,996 | Jun 5, 2026 |
| Jun 4, 2026 | Barbara-Jean Anne Bormann-Kennedy director | AGrant or award Stock Option (Right to Buy)derivative10b5-1 | +32,996 | $6.15 | $203k | 32,996 | Jun 5, 2026 |
| Jun 4, 2026 | John Johnson director | AGrant or award Stock Option (Right to Buy)derivative10b5-1 | +32,996 | $6.15 | $203k | 32,996 | Jun 5, 2026 |
| Jun 4, 2026 | Marla Persky director | AGrant or award Stock Option (Right to Buy)derivative10b5-1 | +32,996 | $6.15 | $203k | 32,996 | Jun 5, 2026 |
| Jun 4, 2026 | Dawn Halkuff director | AGrant or award Stock Option (Right to Buy)derivative10b5-1 | +32,996 | $6.15 | $203k | 32,996 | Jun 5, 2026 |
| Jun 1, 2026 | Beth Hecht See Remarks | SOpen-market sale Common Stock10b5-1 | -16,667 | $6.06 | $101k | 1,176,506 | Jun 2, 2026 |
| May 1, 2026 | Beth Hecht See Remarks | SOpen-market sale Common Stock10b5-1 | -16,667 | $6.23 | $104k | 1,193,173 | May 1, 2026 |
| Apr 1, 2026 | Beth Hecht See Remarks | SOpen-market sale Common Stock10b5-1 | -16,667 | $5.99 | $100k | 1,209,840 | Apr 3, 2026 |
| Mar 30, 2026 | James Aloysius Brady director | SOpen-market sale Common Stock10b5-1 | -10,834 | $5.54 | $60k | 89,166 | Apr 1, 2026 |
| Mar 12, 2026 | Kevin McCulloch See Remarks | MOption exercise Common Stock | +48,894 | $4.09 | $200k | 1,777,721 | Mar 16, 2026 |
| Mar 12, 2026 | Kevin McCulloch See Remarks | MOption exercise Common Stock | +4 | $3.94 | $16 | 1,777,725 | Mar 16, 2026 |
| Mar 12, 2026 | Kevin McCulloch See Remarks | MOption exercise Stock Option (Right to Buy)derivative | -48,894 | $4.09 | $200k | 43,773 | Mar 16, 2026 |
| Mar 12, 2026 | Kevin McCulloch See Remarks | MOption exercise Stock Option (Right to Buy)derivative | -4 | $3.94 | $16 | 79,996 | Mar 16, 2026 |
| Mar 5, 2026 | Steven Pieper See Remarks | MOption exercise Common Stock | +27,891 | $4.09 | $114k | 1,394,904 | Mar 5, 2026 |
| Mar 5, 2026 | Steven Pieper See Remarks | MOption exercise Common Stock | +14,036 | $5.93 | $83k | 1,408,940 | Mar 5, 2026 |
| Mar 5, 2026 | Steven Pieper See Remarks | MOption exercise Stock Option (Right to Buy)derivative | -27,891 | $0.00 | $0 | 0 | Mar 5, 2026 |
| Mar 5, 2026 | Steven Pieper See Remarks | MOption exercise Stock Option (Right to Buy)derivative | -14,036 | $0.00 | $0 | 0 | Mar 5, 2026 |
| Mar 2, 2026 | Beth Hecht See Remarks | SOpen-market sale Common Stock10b5-1 | -16,567 | $6.24 | $103k | 1,226,607 | Mar 4, 2026 |
| Mar 2, 2026 | Beth Hecht See Remarks | SOpen-market sale Common Stock10b5-1 | -100 | $7.06 | $706 | 1,226,507 | Mar 4, 2026 |
| Feb 24, 2026 | Anh Tu Nguyen See Remarks | FTax withholding Common Stock | -29,300 | $6.88 | $202k | 395,023 | Feb 25, 2026 |
| Jan 30, 2026 | Beth Hecht See Remarks | AGrant or award Common Stock | +121,293 | $0.00 | $0 | 1,429,396 | Feb 2, 2026 |
50 of 130 rows shown.
Insiders
Everyone who has filed a Form 4 here.
- Barbara-Jean Anne Bormann-Kennedydirector
- James Aloysius Bradydirector
- Dawn Halkuffdirector
- Beth HechtSee Remarks
- John Johnsonchair, officer, director
- Nerissa Kreherdirector
- Garheng Kongdirector
- Kevin McCullochSee Remarks
- Anh Tu NguyenSee Remarks
- Marla Perskydirector
- Steven PieperSee Remarks
- Jeffrey W Shermandirector
- John P. Schmiddirector, other
- John Patrick Shannon JrSee Remarks
Questions about XERS
Answered from the filings on this page, as of the latest one.
Are insiders buying XERS?
As of Oct 2, 2026, SEC Form 4 filings show 0 open-market buys worth $0 by 0 insiders and 10 open-market sells worth $1.2M by 3 insiders at Xeris Biopharma Holdings, Inc. in the last 90 days, net -$1.2M. Only purchases (code P) and sales (code S) count; grants, option exercises and tax withholding do not.
Who was the last insider to trade XERS on the open market?
Beth Hecht (See Remarks) sold $157k of XERS on Oct 1, 2026 and filed the Form 4 on Oct 2, 2026. InsiderTell scored 21 (weak), under a 10b5-1 plan, with 3 insiders on the same side within 14 days.
How many insiders file Form 4 at Xeris Biopharma Holdings, Inc.?
14 people have filed a Form 4 at Xeris Biopharma Holdings, Inc., among them Barbara-Jean Anne Bormann-Kennedy (director), James Aloysius Brady (director), Dawn Halkuff (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.